2018 Pre-IID Pemphigus and Pemphigoid Symposium

Updated results from the BP-01 phase 2a study of bertilimumab in bullous pemphigoid are being presented at the pre-IID Pemphigus and Pemphigoid Symposium in Orlando, Florida on May 15.  The data will be featured in an oral presentation by Neil Korman, MD, PhD, Director Clinical Trials Unit and the Murdough Family Center for Psoriasis, University Hospitals Cleveland Medical Center, and Professor of Dermatology, Case Western Reserve University School of Medicine, and a member of the Company’s Scientific Advisory Board, and in a poster to be presented by Immune’s Chief Medical and Operating Officer, Tony Fiorino, MD, PhD.  The poster is available here.

Download PDF